Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks muscle loss in lung patients on common meds

NCT ID NCT07332117

Knowledge-focused Sponsor: Royal Brompton & Harefield NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study looks at how anti-fibrotic medications affect body composition in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Researchers will use bioelectrical impedance analysis (BIA) and muscle ultrasound to track changes in muscle and fat mass. The goal is to see if these tools are practical and acceptable for monitoring patients starting nintedanib or pirfenidone. About 30 adults will be followed for 4 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients being newly commenced on anti-fibrotic medication as part of their clinical care (either nintedanib or pirfenidone)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis * Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone) * Subject aged \> 18 years * Able to willingly give consent Exclusion Criteria: * Co-morbidities currently requiring enteral feeding * Weight loss \> 10% in preceding 3-6 months * Significant musculoskeletal issues that may impact muscle mass * End of life care (expected \< 6 weeks left to live) * Previous anti-fibrotic use * Currently on \> Prednisolone 10mg daily * Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM) * Heart failure * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis (IPF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic pulmonary fibrosis (IPF) Progressive pulmonary fibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Brompton Hospital

    RECRUITING

    London, SW36NP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.